Non-Alcoholic Steatohepatitis (NASH) Market 2027 By Drug Type, Sales Channel and Geography | The Insight Partners

Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Drug Type (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc); Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy) and Geography

Report Code: TIPRE00009653 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

MARKET DYNAMICS

Growing prevalence of chronic liver conditions is expected to drive the market growth In addition, improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, side-effects and risks associated with NASH therapeutics may impede the market growth.

MARKET SCOPE

The "Global Non-Alcoholic Steatohepatitis (NASH) Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Non-Alcoholic Steatohepatitis (NASH) Market with detailed market segmentation by, drug type, sales channel, and geography. The Global Non-Alcoholic Steatohepatitis (NASH) Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Non-Alcoholic Steatohepatitis (NASH) Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Global Non-Alcoholic Steatohepatitis (NASH) Market is segmented on the basis of drug type and sales channel. Based on drug type, it is classified into vitamin E & pioglitazone, ocaliva, elafibranor, selonsertib and cenicriviroc. Based on sales channel, it is divided into hospital pharmacy, online provider and retail pharmacy.
?

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Non-Alcoholic Steatohepatitis (NASH) Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Non-Alcoholic Steatohepatitis (NASH) Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Non-Alcoholic Steatohepatitis (NASH) Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Non-Alcoholic Steatohepatitis (NASH) Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Non-Alcoholic Steatohepatitis (NASH) Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Non-Alcoholic Steatohepatitis (NASH) Market are anticipated to lucrative growth opportunities in the future with the rising demand for Non-Alcoholic Steatohepatitis (NASH) Market in the global market. Below mentioned is the list of few companies engaged in the Non-Alcoholic Steatohepatitis (NASH) Market.

The report also includes the profiles of key Non-Alcoholic Steatohepatitis (NASH) Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Allergan plc. (Tobira Therapeutics)
- Cadila Healthcare Limited
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd
- Gemphire Therapeutics Inc.
- Genfit SA
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Novartis International AG
- Shire Plc.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization `options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Non-Alcoholic Steatohepatitis (NASH) Market - By Drug Type
1.3.2 Non-Alcoholic Steatohepatitis (NASH) Market - By Sales Channel
1.3.3 Non-Alcoholic Steatohepatitis (NASH) Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET - GLOBAL MARKET ANALYSIS
6.1. NON-ALCOHOLIC STEATOHEPATITIS (NASH) - GLOBAL MARKET OVERVIEW
6.2. NON-ALCOHOLIC STEATOHEPATITIS (NASH) - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. VITAMIN E AND PIOGLITAZONE
7.3.1. Overview
7.3.2. Vitamin E and Pioglitazone Market Forecast and Analysis
7.4. OCALIVA
7.4.1. Overview
7.4.2. Ocaliva Market Forecast and Analysis
7.5. ELAFIBRANOR
7.5.1. Overview
7.5.2. Elafibranor Market Forecast and Analysis
7.6. SELONSERTIB
7.6.1. Overview
7.6.2. Selonsertib Market Forecast and Analysis
7.7. CENICRIVIROC
7.7.1. Overview
7.7.2. Cenicriviroc Market Forecast and Analysis
8. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET - REVENUE AND FORECASTS TO 2027 - SALES CHANNEL
8.1. OVERVIEW
8.2. SALES CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACY
8.3.1. Overview
8.3.2. Hospital Pharmacy Market Forecast and Analysis
8.4. ONLINE PROVIDER
8.4.1. Overview
8.4.2. Online Provider Market Forecast and Analysis
8.5. RETAIL PHARMACY
8.5.1. Overview
8.5.2. Retail Pharmacy Market Forecast and Analysis
9. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.1.2 North America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis
9.1.3 North America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Drug Type
9.1.4 North America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Sales Channel
9.1.5 North America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Countries
9.1.5.1 United States Non-Alcoholic Steatohepatitis (NASH) Market
9.1.5.1.1 United States Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.1.5.1.2 United States Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.1.5.2 Canada Non-Alcoholic Steatohepatitis (NASH) Market
9.1.5.2.1 Canada Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.1.5.2.2 Canada Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.1.5.3 Mexico Non-Alcoholic Steatohepatitis (NASH) Market
9.1.5.3.1 Mexico Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.1.5.3.2 Mexico Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.2. EUROPE
9.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis
9.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Drug Type
9.2.4 Europe Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Sales Channel
9.2.5 Europe Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Non-Alcoholic Steatohepatitis (NASH) Market
9.2.5.1.1 Germany Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.2.5.1.2 Germany Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.2.5.2 France Non-Alcoholic Steatohepatitis (NASH) Market
9.2.5.2.1 France Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.2.5.2.2 France Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.2.5.3 Italy Non-Alcoholic Steatohepatitis (NASH) Market
9.2.5.3.1 Italy Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.2.5.3.2 Italy Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.2.5.4 Spain Non-Alcoholic Steatohepatitis (NASH) Market
9.2.5.4.1 Spain Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.2.5.4.2 Spain Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.2.5.5 United Kingdom Non-Alcoholic Steatohepatitis (NASH) Market
9.2.5.5.1 United Kingdom Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.2.5.5.2 United Kingdom Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis
9.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Drug Type
9.3.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Sales Channel
9.3.5 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Non-Alcoholic Steatohepatitis (NASH) Market
9.3.5.1.1 Australia Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.3.5.1.2 Australia Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.3.5.2 China Non-Alcoholic Steatohepatitis (NASH) Market
9.3.5.2.1 China Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.3.5.2.2 China Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.3.5.3 India Non-Alcoholic Steatohepatitis (NASH) Market
9.3.5.3.1 India Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.3.5.3.2 India Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.3.5.4 Japan Non-Alcoholic Steatohepatitis (NASH) Market
9.3.5.4.1 Japan Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.3.5.4.2 Japan Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.3.5.5 South Korea Non-Alcoholic Steatohepatitis (NASH) Market
9.3.5.5.1 South Korea Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.3.5.5.2 South Korea Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.4.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis
9.4.3 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Drug Type
9.4.4 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Sales Channel
9.4.5 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Non-Alcoholic Steatohepatitis (NASH) Market
9.4.5.1.1 South Africa Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.4.5.1.2 South Africa Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.4.5.2 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Market
9.4.5.2.1 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.4.5.2.2 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.4.5.3 U.A.E Non-Alcoholic Steatohepatitis (NASH) Market
9.4.5.3.1 U.A.E Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.4.5.3.2 U.A.E Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.5.2 South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis
9.5.3 South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Drug Type
9.5.4 South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Sales Channel
9.5.5 South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Non-Alcoholic Steatohepatitis (NASH) Market
9.5.5.1.1 Brazil Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.5.5.1.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
9.5.5.2 Argentina Non-Alcoholic Steatohepatitis (NASH) Market
9.5.5.2.1 Argentina Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type
9.5.5.2.2 Argentina Non-Alcoholic Steatohepatitis (NASH) Market by Sales Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET, KEY COMPANY PROFILES
11.1. ALLERGAN PLC. (TOBIRA THERAPEUTICS)
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. CADILA HEALTHCARE LIMITED
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. CONATUS PHARMACEUTICALS INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GALMED PHARMACEUTICALS LTD
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GEMPHIRE THERAPEUTICS INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. GENFIT SA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GILEAD SCIENCES, INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. INTERCEPT PHARMACEUTICALS, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. NOVARTIS INTERNATIONAL AG
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SHIRE PLC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Allergan plc. (Tobira Therapeutics)
2. Cadila Healthcare Limited
3. Conatus Pharmaceuticals Inc.
4. Galmed Pharmaceuticals Ltd
5. Gemphire Therapeutics Inc.
6. Genfit SA
7. Gilead Sciences, Inc.
8. Intercept Pharmaceuticals, Inc.
9. Novartis International AG
10. Shire Plc.

TIPRE00009653
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking